Search
Ivabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the … Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing
Radium Ra 223 dichloride
go.drugbank.com/drugs/DB08913ApprovedInvestigationalRadium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. … It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawn[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDoxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSulfasalazine
go.drugbank.com/drugs/DB00795ApprovedInvestigational[A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … [A255592] Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDSHuman immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIntravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and io...
Products: Gamimune N 5% (iv), Gamimune N 10% (iv)Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
Fludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalIt is administered by intravenous injection. … Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.